tirzepatide and semaglutide vs. for Weight Loss Popular weight loss drugs could

W., & Lee, K

Nevertheless, long-term safety data, high-dose exposure effects, and use in vulnerable populations remain insufficiently characterized

The good news is that once-weekly dosing provides significant wiggle room

Additionally, incorporating behavioral strategies, such as gradual exposure to new foods and positive reinforcement, can improve food acceptance and mealtime behaviors[91]

Phase 2 (NA-931, 13 weeks): Key characteristics: Lowest GI adverse event rates of any drug in this comparison by a wide margin 83% of all GI events classified as "insignificant" No clinically meaningful difference in GI events between NA-931 and placebo No muscle loss observed However, the study was only 13 weeks with 125 participants -- tolerability at higher doses and longer durations is unknown Side-by-Side Comparison# NR = not reported